First-line Therapy
Showing 1 - 25 of >10,000
Colorectal Cancer Trial in Tai'an (Tas-102(Suyuan) combined with bevacizumab)
Not yet recruiting
- Colorectal Cancer
- Tas-102(Suyuan) combined with bevacizumab
-
Tai'an, Shandong, ChinaThe Second Affiliated Hospital of Shandong First Medical Univers
Oct 14, 2023
Colorectal Cancer Trial in Shanghai (Fruquintinib+mFOLFOX6/FOLFIRI)
Recruiting
- Colorectal Cancer
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 23, 2023
Stomach Tumors Trial in Shanghai (Fruquintinib, Sintilimab)
Active, not recruiting
- Stomach Neoplasms
-
Shanghai, ChinaRenji Hospital
Apr 3, 2023
Advanced Hepatocellular Carcinoma Trial in Guangzhou (adebrelimab, camrelizumab plus apatinib)
Not yet recruiting
- Advanced Hepatocellular Carcinoma
- adebrelimab, camrelizumab plus apatinib
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital
Jun 21, 2023
TNBC Trial in Shanghai (PM8002, nab-paclitaxel)
Recruiting
- TNBC
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 25, 2023
Pleural Mesothelioma Trial in Guangzhou (Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin)
Not yet recruiting
- Pleural Mesothelioma
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jul 3, 2023
Unrescetable Hepatocellular Carcinoma Trial in Tianjin (HAIC+Durvalumab+Tremelimumab+Bevacizumab)
Not yet recruiting
- Unrescetable Hepatocellular Carcinoma
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital Airport Hospital
May 16, 2023
Unrescetable Hepatocellular Carcinoma Trial in Tianjin (HAIC+Cadonilimab+Bevacizumab)
Not yet recruiting
- Unrescetable Hepatocellular Carcinoma
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital Airport Hospital
Apr 7, 2023
Intrahepatic Cholangiocarcinoma Trial in Shanghai (Cadonilimab+Gem/Cis)
Active, not recruiting
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaEastern hepatobilliary surgery hospital
Mar 22, 2023
Hepatocellular Carcinoma Trial in Hangzhou (PM8002, FOLFOX regimen)
Recruiting
- Hepatocellular Carcinoma
- PM8002
- FOLFOX regimen
-
Hangzhou, Zhejiang, ChinaCancer Hospital of The University of Chinese Academy of Sciences
May 19, 2023
Biliary Tract Carcinoma Trial in Beijing (Gemcitabine, S1, Tislelizumab)
Not yet recruiting
- Biliary Tract Carcinoma
- Gemcitabine
- +2 more
-
Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Apr 10, 2023
Efficacy and Safety of ICIs as First-line Therapy for Advanced
Not yet recruiting
- Malignant Tumor
- +2 more
-
Chongqing, Chongqing, Chinathe second affiliated hospital of Army medical university
May 16, 2023
Metastatic Uveal Melanoma Trial in Grand Rapids (IDE196, Crizotinib, Pembrolizumab)
Recruiting
- Metastatic Uveal Melanoma
- IDE196
- +5 more
-
Grand Rapids, MichiganThe Cancer and Hematology Centers
Aug 14, 2023
NSCLC Trial in Chendu (Almonertinib)
Recruiting
- Non-small Cell Lung Cancer
-
Chendu, Sichuan, ChinaWest China Hospital,Sichuan University
Dec 14, 2022
Oral Cavity Squamous Cell Carcinoma Trial in Yichang (Sintilimab, Radiotherapy)
Recruiting
- Oral Cavity Squamous Cell Carcinoma
- Sintilimab
- Radiotherapy
-
Yichang, Hubei, ChinaDepartment of Medical Oncology, Central Hospital of Yichang City
Feb 18, 2023
Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Epcoritamab
- Lenalidomide
- (no location specified)
Jan 20, 2023
Small Cell Lung Cancer Extensive Stage Trial (Pembrolizumab, Plinabulin plus Etoposide and Platinum)
Not yet recruiting
- Small Cell Lung Cancer Extensive Stage
- Pembrolizumab, Plinabulin plus Etoposide and Platinum
- (no location specified)
Feb 15, 2023
B-cell Lymphoma Trial in Beijing (Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide)
Not yet recruiting
- B-cell Lymphoma
- Relmacabtagene Autoleucel
- +2 more
-
Beijing, Beijing, China
- +1 more
Oct 19, 2022
Metastatic Pancreatic Cancer Trial in Lyon (Niraparib)
Not yet recruiting
- Metastatic Pancreatic Cancer
-
Lyon, FranceCentre Léon Bérard
Jul 4, 2022
Pancreatic Tumors Trial in Guangzhou (Surufatinib, Sintilimab, AG)
Not yet recruiting
- Pancreatic Neoplasms
- Surufatinib
- +2 more
-
Guangzhou, Guangdong, ChinaCancer center of SunYat-sen University
Jul 28, 2022
Leukemia, Chronic Lymphatic Trial in Stuttgart, Tuebingen (Peptide Vaccine, Imiquimod)
Completed
- Leukemia, Chronic Lymphatic
- Peptide Vaccine
- Imiquimod
-
Stuttgart, Baden-Wuerttemberg, Germany
- +4 more
Nov 24, 2022